Tumor DNA Blood Test to Guide Breast Cancer Treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You can carry out your daily activities with little or no help (ECOG 0-1).
- Your cancer is HER2-negative (confirmed by a lab test) and has spread to other parts of the body.
- You have at least one tumor that can be measured on an imaging scan.
- You have not had an antibody-drug conjugate (ADC) therapy that attacks the same target with the same drug before.
- Your brain metastases are either absent or have been fully treated and are stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This trial is testing whether monitoring ctDNA (genetic material from the tumor in your blood) can help guide treatment for HER2-positive breast cancer before surgery. It is for people with early-stage (Stage II or III) disease who have not yet started treatment.
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
Hear when a new Metastatic Breast Cancer ( HER2 Negative) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.